Nibio Initiates Japanese Vaccine Adjuvant Research Consortium
This article was originally published in PharmAsia News
Executive SummaryJapan's National Institute of Biomedical Research has established a research team to tackle research and development of next-generation adjuvants for vaccines
You may also be interested in...
NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.